Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Inclusion Criteria:

- Diagnosis of adult-onset Psoriatic Arthritis (PsA) of at least 6 months' duration as
defined by the Classification Criteria for Psoriatic Arthritis (CASPAR criteria)

- Active Psoriatic Skin Lesions or a documented history of Psoriasis

- Active Arthritis with ≥ 3 tender joints at Screening and Baseline, ≥ 3 swollen joints
at Screening and Baseline and fulfilling at least 1 of the following 2 criteria during
the Screening Period:

1. Erythrocyte Sedimentation Rate (ESR) (Westergren) ≥ 28 mm/hour

2. C-reactive protein (CRP) > Upper Limit Normal (ULN)

- Failure to 1 or more treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Exclusion Criteria:

- Diagnosis of any other inflammatory Arthritis or known diagnosis of Fibromyalgia

- Exposure to more than 1 Tumor Necrosis Factor α (TNFα) antagonist or to more than 2
previous biological response modifiers for PsA or Psoriasis

- Any non-biological systemic treatment of Psoriasis; phototherapy; topical agents

- History of chronic or recurrent infections

- High risk of infection

- Live vaccination within the 8 weeks prior to Baseline

- Concurrent malignancy or a history of malignancy

- Class III or IV congestive Heart Failure - New York Heart Association (NYHA)

- Demyelinating disease of the central nervous system

- Clinically significant laboratory abnormalities